KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Inventory (2016 - 2025)

Amgen has reported Inventory over the past 17 years, most recently at $6.2 billion for Q4 2025.

  • Quarterly results put Inventory at $6.2 billion for Q4 2025, down 11.05% from a year ago — trailing twelve months through Dec 2025 was $6.2 billion (down 11.05% YoY), and the annual figure for FY2025 was $6.2 billion, down 11.05%.
  • Inventory for Q4 2025 was $6.2 billion at Amgen, down from $6.3 billion in the prior quarter.
  • Over the last five years, Inventory for AMGN hit a ceiling of $9.5 billion in Q4 2023 and a floor of $4.0 billion in Q1 2021.
  • Median Inventory over the past 5 years was $5.0 billion (2023), compared with a mean of $5.8 billion.
  • Biggest five-year swings in Inventory: soared 93.06% in 2023 and later dropped 26.48% in 2024.
  • Amgen's Inventory stood at $4.1 billion in 2021, then grew by 20.66% to $4.9 billion in 2022, then soared by 93.06% to $9.5 billion in 2023, then dropped by 26.48% to $7.0 billion in 2024, then fell by 11.05% to $6.2 billion in 2025.
  • The last three reported values for Inventory were $6.2 billion (Q4 2025), $6.3 billion (Q3 2025), and $6.6 billion (Q2 2025) per Business Quant data.